SynVaccine is a start-up that is designing and validating synthetic viruses as the basis for revolutionary new cancer immunotherapies and vaccines against infectious disease.
 
The company’s innovations are based on disruptive new technologies licensed exclusively from the Tel Aviv University and the Weizmann Institute – technologies that enable design-by-computer of viral genomes and the physical DNA editing of viral vaccine genome libraries.

These technologies are positioned to leapfrog currently used, trial-and-error-based technologies for the development of viro-therapies and vaccines, making it possible to rapidly create a pipeline of new products for overcoming major health challenges.